Klaria Pharma Holding AB (publ.) receives `Notice of Allowance' from the United Stated Patent and Trademark Office (USPTO) for a product patent protecting its most advanced development asset, Sumatriptan Alginate Film. With this approval of a completely new patent, Sumatriptan Alginate Film will enjoy patent-protected market exclusivity in the United States until 2036. This extends the period of market exclusivity in the US by 7 years, thereby increasing the projected cumulative revenue of the product by more than USD 1 billion. Moreover, the breadth of claims in the patent is wide, solidifying the market exclusivity in the patent period. The approval marks the second time the USPTO approves a compound/Alginate Film combination patent that protects an individual compound formulated in Klaria's proprietary Alginate Film. Thus, the approval validates Klaria's patent strategy which calls for filing of compound/Alignate Film combination patents for all its development products. This approval is confirmation of Klaria's ability to successfully develop unique, patent-protected products that build on the base technology alginate film patents owned by Klaria. Klaria's intellectual property strategy therefore not only relies on the strength of the `base' technology patent, but also extends the patent life of the individual products through compound/Alginate Film combination patents.